246 related articles for article (PubMed ID: 32512936)
1. A Co-Delivery System of Curcumin and p53 for Enhancing the Sensitivity of Drug-Resistant Ovarian Cancer Cells to Cisplatin.
Guo X; Fang Z; Zhang M; Yang D; Wang S; Liu K
Molecules; 2020 Jun; 25(11):. PubMed ID: 32512936
[TBL] [Abstract][Full Text] [Related]
2. A nano-targeted co-delivery system based on gene regulation and molecular blocking strategy for synergistic enhancement of platinum chemotherapy sensitivity in ovarian cancer.
Song M; Fang Z; Wang J; Liu K
Int J Pharm; 2023 Jun; 640():123022. PubMed ID: 37156306
[TBL] [Abstract][Full Text] [Related]
3. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
4. Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.
Zhao MD; Li JQ; Chen FY; Dong W; Wen LJ; Fei WD; Zhang X; Yang PL; Zhang XM; Zheng CH
Int J Nanomedicine; 2019; 14():9453-9467. PubMed ID: 31819443
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.
Gong S; Chen Y; Meng F; Zhang Y; Li C; Zhang G; Huan W; Wu F
Cell Prolif; 2018 Oct; 51(5):e12474. PubMed ID: 30069985
[TBL] [Abstract][Full Text] [Related]
6. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
[TBL] [Abstract][Full Text] [Related]
8. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
9.
Hou XF; Xu LP; Song HY; Li S; Wu C; Wang JF
World J Gastroenterol; 2017 Mar; 23(10):1796-1803. PubMed ID: 28348485
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1.
Zhang XL; Sun BL; Tian SX; Li L; Zhao YC; Shi PP
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3635-3644. PubMed ID: 31114988
[TBL] [Abstract][Full Text] [Related]
11. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
12. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
13. [Inhibition of Topo II alpha gene expression and reversing of drug resistance in multi-drug resistant epithelial ovarian cancer cells induced by RNA interference in vitro].
He J; Li L; Tang BJ; Zhang W; Li DR; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):686-90. PubMed ID: 20079182
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
Zhang C; Wang M; Shi C; Shi F; Pei C
Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
[TBL] [Abstract][Full Text] [Related]
15. Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo.
Gu J; Tang Y; Liu Y; Guo H; Wang Y; Cai L; Li Y; Wang B
Cancer Lett; 2014 Feb; 343(2):200-9. PubMed ID: 24161623
[TBL] [Abstract][Full Text] [Related]
16. Combination Therapy of Lung Cancer Using Layer-by-Layer Cisplatin Prodrug and Curcumin Co-Encapsulated Nanomedicine.
Hong Y; Che S; Hui B; Wang X; Zhang X; Ma H
Drug Des Devel Ther; 2020; 14():2263-2274. PubMed ID: 32606596
[TBL] [Abstract][Full Text] [Related]
17. IDO1 Modulates the Sensitivity of Epithelial Ovarian Cancer Cells to Cisplatin through ROS/p53-Dependent Apoptosis.
Wang H; Luo Y; Ran R; Li X; Ling H; Wen F; Yu T
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233312
[TBL] [Abstract][Full Text] [Related]
18. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
[TBL] [Abstract][Full Text] [Related]
19. Co-Delivery of Docetaxel and Curcumin via Nanomicelles for Enhancing Anti-Ovarian Cancer Treatment.
Hu Y; Ran M; Wang B; Lin Y; Cheng Y; Zheng S
Int J Nanomedicine; 2020; 15():9703-9715. PubMed ID: 33299312
[TBL] [Abstract][Full Text] [Related]
20. [Biological effect of down-regulating of MTRR gene on cisplatin-resistant ovarian cancer SKOV3 cells in vitro and in vivo studies].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):126-34. PubMed ID: 26917482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]